{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:32:12Z","timestamp":1783179132368,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Neurotrophic keratopathy (NK) is a degenerative corneal disease caused by damage of trigeminal innervation. The purpose of this study is to evaluate the clinical outcomes and patient-reported satisfaction of treatment with amniotic membrane transplantation (AMT) or cenegermin eye drops in patients with NK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical charts of patients with NK treated with AMT (group A) or cenegermin eye drops (group B), with at least 12\u00a0months of follow-up, were reviewed for demographics, medical history, corneal healing, and disease recurrence. Patient satisfaction was evaluated by a newly developed questionnaire investigating patient\u2019s appreciation of treatment of NK (2 items) and satisfaction with NK treatment outcomes (5 items).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the end of treatment, complete corneal healing was observed in 13\/15 (86%) patients in group A and in 23\/24 (96%) in group B. At 12\u00a0months follow-up, 6\/13 patients (46%) in group A and 3\/23 patients (13%) in group B showed recurrence of NK (<jats:italic>p<\/jats:italic>\u2009=\u20090.037).<\/jats:p>\n                <jats:p>Survival analysis showed that group B remained recurrence free for a significantly longer period of time than the group A (<jats:italic>p<\/jats:italic>\u2009=\u20090.028). Patients in group B showed a significantly higher satisfaction when compared with patients in group A (total score: 65.7\u2009\u00b1\u200915.7 vs 47.4\u2009\u00b1\u200912.8, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), both in terms of patients\u2019 appreciation of treatment (78.3\u2009\u00b1\u200915.9 vs 52.2\u2009\u00b1\u200930, <jats:italic>p<\/jats:italic>\u2009=\u20090.020) and satisfaction with treatment outcomes (60.7\u2009\u00b1\u200921 vs 45.4\u2009\u00b1\u200913.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.037).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment of NK with cenegermin was associated with long-term maintenance of corneal integrity and a higher degree of patient satisfaction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-021-05431-6","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T10:05:01Z","timestamp":1633946701000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation"],"prefix":"10.1007","volume":"260","author":[{"given":"Marta","family":"Sacchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Komaiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bruscolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella Anna Maria","family":"Colabelli Gisoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Pocobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-991X","authenticated-orcid":false,"given":"Alessandro","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"5431_CR1","doi-asserted-by":"publisher","unstructured":"Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M (2016) Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. https:\/\/doi.org\/10.1002\/jcp.25623","DOI":"10.1002\/jcp.25623"},{"key":"5431_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S45921","volume":"8","author":"M Sacchetti","year":"2014","unstructured":"Sacchetti M, Lambiase A (2014) Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol 8:571\u2013579. https:\/\/doi.org\/10.2147\/OPTH.S45921","journal-title":"Clin Ophthalmol"},{"key":"5431_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.eye.6700616","volume":"17","author":"S Bonini","year":"2003","unstructured":"Bonini S, Rama P, Olzi D, Lambiase A (2003) Neurotrophic keratitis. Eye (Lond) 17:989\u2013995. https:\/\/doi.org\/10.1038\/sj.eye.6700616","journal-title":"Eye (Lond)"},{"key":"5431_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1358\/dot.2017.53.11.2722395","volume":"53","author":"M Sacchetti","year":"2017","unstructured":"Sacchetti M, Bruscolini A, Lambiase A (2017) Cenegermin for the treatment of neurotrophic keratitis. Drugs Today 53:585\u2013595. https:\/\/doi.org\/10.1358\/dot.2017.53.11.2722395","journal-title":"Drugs Today"},{"key":"5431_CR5","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","volume":"125","author":"Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F, Group RS","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F, Group RS (2018) Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125:1468\u20131471. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.004","journal-title":"Ophthalmology"},{"key":"5431_CR6","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F, Group RS","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F, Group RS (2018) Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125:1332\u20131343. https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.022","journal-title":"Ophthalmology"},{"key":"5431_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","volume":"127","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R (2020) Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 127:14\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.020","journal-title":"Ophthalmology"},{"key":"5431_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","volume":"80","author":"ED Deeks","year":"2020","unstructured":"Deeks ED, Lamb YN (2020) Cenegermin: a review in neurotrophic keratitis. Drugs 80:489\u2013494. https:\/\/doi.org\/10.1007\/s40265-020-01289-w","journal-title":"Drugs"},{"key":"5431_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/archopht.121.8.1189","volume":"121","author":"A Khodadoust","year":"2003","unstructured":"Khodadoust A, Quinter AP (2003) Microsurgical approach to the conjunctival flap. Arch Ophthalmol 121:1189\u20131193. https:\/\/doi.org\/10.1001\/archopht.121.8.1189","journal-title":"Arch Ophthalmol"},{"key":"5431_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","volume":"66","author":"HS Dua","year":"2018","unstructured":"Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, Shortt AJ, Geerling G, Nubile M, Figueiredo FC, Rauz S, Mastropasqua L, Rama P, Baudouin C (2018) Neurotrophic keratopathy. Prog Retin Eye Res 66:107\u2013131. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.04.003","journal-title":"Prog Retin Eye Res"},{"key":"5431_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/01.ico.0000153102.19776.80","volume":"24","author":"S Khokhar","year":"2005","unstructured":"Khokhar S, Natung T, Sony P, Sharma N, Agarwal N, Vajpayee RB (2005) Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea 24:654\u2013660","journal-title":"Cornea"},{"key":"5431_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/bjo.84.8.826","volume":"84","author":"HJ Chen","year":"2000","unstructured":"Chen HJ, Pires RT, Tseng SC (2000) Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol 84:826\u2013833","journal-title":"Br J Ophthalmol"},{"key":"5431_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/08820538.2013.768678","volume":"29","author":"E Turkoglu","year":"2014","unstructured":"Turkoglu E, Celik E, Alagoz G (2014) A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol 29:119\u2013126. https:\/\/doi.org\/10.3109\/08820538.2013.768678","journal-title":"Semin Ophthalmol"},{"key":"5431_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","volume":"18","author":"S Saad","year":"2020","unstructured":"Saad S, Abdelmassih Y, Saad R, Guindolet D, Khoury SE, Doan S, Cochereau I, Gabison EE (2020) Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf 18:231\u2013236. https:\/\/doi.org\/10.1016\/j.jtos.2019.11.008","journal-title":"Ocul Surf"},{"key":"5431_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1023\/B:CATB.0000046067.25057.0a","volume":"5","author":"S Burman","year":"2004","unstructured":"Burman S, Tejwani S, Vemuganti GK, Gopinathan U, Sangwan VS (2004) Ophthalmic applications of preserved human amniotic membrane: a review of current indications. Cell Tissue Banking 5:161\u2013175. https:\/\/doi.org\/10.1023\/B:CATB.0000046067.25057.0a","journal-title":"Cell Tissue Banking"},{"key":"5431_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0161-6420(99)90444-X","volume":"106","author":"FE Kruse","year":"1999","unstructured":"Kruse FE, Rohrschneider K, Volcker HE (1999) Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology 106:1504\u20131510. discussion 1511. https:\/\/doi.org\/10.1016\/S0161-6420(99)90444-X","journal-title":"Ophthalmology"},{"key":"5431_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/bjo.83.6.748","volume":"83","author":"HS Dua","year":"1999","unstructured":"Dua HS, Azuara-Blanco A (1999) Amniotic membrane transplantation. Br J Ophthalmol 83:748\u2013752. https:\/\/doi.org\/10.1136\/bjo.83.6.748","journal-title":"Br J Ophthalmol"},{"key":"5431_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ajo.2007.06.028","volume":"144","author":"M Sacchetti","year":"2007","unstructured":"Sacchetti M, Baiardini I, Lambiase A, Aronni S, Fassio O, Gramiccioni C, Bonini S, Bonini S (2007) Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. Am J Ophthalmol 144:557\u2013563. https:\/\/doi.org\/10.1016\/j.ajo.2007.06.028","journal-title":"Am J Ophthalmol"},{"key":"5431_CR19","first-page":"5","volume":"140","author":"R Likert","year":"1932","unstructured":"Likert R (1932) A technique for the measurement of attitudes. Arch Psychol 140:5\u201355","journal-title":"Arch Psychol"},{"key":"5431_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000354380","volume":"231","author":"F Semeraro","year":"2014","unstructured":"Semeraro F, Forbice E, Romano V, Angi M, Romano MR, Filippelli ME, Di Iorio R, Costagliola C (2014) Neurotrophic keratitis. Ophthalmologica 231:191\u2013197. https:\/\/doi.org\/10.1159\/000354380","journal-title":"Ophthalmologica"},{"key":"5431_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/jcp.25623","volume":"232","author":"L Mastropasqua","year":"2017","unstructured":"Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M (2017) Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol 232:717\u2013724. https:\/\/doi.org\/10.1002\/jcp.25623","journal-title":"J Cell Physiol"},{"key":"5431_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/tjo.tjo_5_20","volume":"10","author":"OG Mead","year":"2020","unstructured":"Mead OG, Tighe S, Tseng SCG (2020) Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis. Taiwan J Ophthalmol 10:13\u201321. https:\/\/doi.org\/10.4103\/tjo.tjo_5_20","journal-title":"Taiwan J Ophthalmol"},{"key":"5431_CR23","first-page":"47","volume":"26","author":"B Ivekovic","year":"2002","unstructured":"Ivekovic B, Tedeschi-Reiner E, Petric I, Novak-Laus K, Bradic-Hammoud M (2002) Amniotic membrane transplantation for ocular surface reconstruction in neurotrophic corneal ulcera. Coll Antropol 26:47\u201354","journal-title":"Coll Antropol"},{"key":"5431_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jtos.2019.09.002","volume":"17","author":"A Di Zazzo","year":"2019","unstructured":"Di Zazzo A, Coassin M, Varacalli G, Galvagno E, De Vincentis A, Bonini S (2019) Neurotrophic keratopathy: pros and cons of current treatments. Ocul Surf 17:619\u2013623. https:\/\/doi.org\/10.1016\/j.jtos.2019.09.002","journal-title":"Ocul Surf"},{"key":"5431_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajo.2020.04.036","volume":"217","author":"L Mastropasqua","year":"2020","unstructured":"Mastropasqua L, Lanzini M, Dua HS, Du A, Di Nicola M, Calienno R, Bondi J, Said DG, Nubile M (2020) In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. Am J Ophthalmol 217:278\u2013286. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.036","journal-title":"Am J Ophthalmol"},{"key":"5431_CR26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1055\/a-1274-3675","volume":"237","author":"SB Zwingelberg","year":"2020","unstructured":"Zwingelberg SB, Bachmann BO, Cursiefen C (2020) Real life data on efficacy and safety of topical NGF eye drops (cenegermin). Klin Monatsbl Augenheilkd 237:1455\u20131461. https:\/\/doi.org\/10.1055\/a-1274-3675","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"5431_CR27","first-page":"1063","volume":"41","author":"A Lambiase","year":"2000","unstructured":"Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L (2000) Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 41:1063\u20131069","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5431_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/ICU.0b013e3283543b61","volume":"23","author":"A Lambiase","year":"2012","unstructured":"Lambiase A, Sacchetti M, Bonini S (2012) Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol 23:296\u2013302. https:\/\/doi.org\/10.1097\/ICU.0b013e3283543b61","journal-title":"Curr Opin Ophthalmol"},{"key":"5431_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jtos.2020.09.007","volume":"19","author":"RE Ruiz-Lozano","year":"2021","unstructured":"Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, Merayo-Lloves J, Rodriguez-Garcia A (2021) The molecular basis of neurotrophic keratopathy: diagnostic and therapeutic implications. A review. Ocul Surf 19:224\u2013240. https:\/\/doi.org\/10.1016\/j.jtos.2020.09.007","journal-title":"Ocul Surf"},{"key":"5431_CR30","doi-asserted-by":"publisher","unstructured":"Bernabei F, Roda M, Buzzi M, Pellegrini M, Giannaccare G, Versura P (2019) Blood-based treatments for severe dry eye disease: the need of a consensus J Clin Med 8.https:\/\/doi.org\/10.3390\/jcm8091478","DOI":"10.3390\/jcm8091478"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05431-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:06:34Z","timestamp":1646118394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05431-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5431"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05431-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to add the missing compact agreement Open Access funding note.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics committee of Sapienza University of Rome ref # 5969. The study was performed in accordance with the tenets of the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Marta Sacchetti: Consultant for Domp\u00e9 Farmaceutici SPA (Milan, Italy).Prof. Alessandro Lambiase: Consultant\/advisor and Licensed intellectual property\u2009\u2212\u2009Domp\u00e9 Farmaceutici SpA (Milan, Italy).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}